Закрыть
Pelubio
Pelubio
Polmaksib
Polmaksib
DiklArtis
DiklArtis
KetArtis
KetArtis
Products line
Polmaksib

Polmaksib

Download instruction
Ask a Question
About the drug
For specialists

Polmaxib® is an innovative selective nonsteroidal anti–inflammatory drug (NSAID), the active ingredient of which is polmacoxib.


The drug Polmaxib® is indicated for the elimination of pain and inflammation in osteoarthritis in adult patients. The use of the drug only once a day makes the Floor maxi b® convenient to use.


Polmacoxib was developed in South Korea and has been successfully used in medical practice since 2015.


Indications for use

- for symptomatic therapy of osteoarthritis

- reduce pain and inflammation at the time of use


Vacation conditions

They are released by prescription.



Instructions for the medical use of the drug Polmaxib® RU LP-007663 from 07.12.2021.

Polmaxib® is an innovative1 selective nonsteroidal anti–inflammatory drug (NSAID) with a dual mechanism of action: the drug is a selective inhibitor of cyclooxygenase-2 (COX-2) and an inhibitor of carbonic anhydrase I/II2.


The drug Polmaxib® was developed in South Korea and registered for the treatment of osteoarthritis in February 20153.


Composition per capsule:

Active substance: Polmacoxib - 2.0 mg


Pharmacodynamics

Polmacoxib is a selective nonsteroidal anti-inflammatory drug (NSAID) cyclooxygenase-2 (COX-2). It selectively inhibits COX-2 of the COX family.


Polmacoxib is able to bind to carbonic anhydrase, which has a characteristic mechanism in comparison with traditional NSAIDs or selective NSAIDs COX-2. Carbonic anhydrase is present in large quantities in the cardiovascular system, for example, in red blood cells, while COX-2 is induced at the site of inflammation. Experimental studies have shown that the inhibitory effect of polmacoxib on COX-2 was further reduced with the simultaneous presence of COX-2 and carbonic anhydrase compared with the experiment in the presence of COX-2 alone. In other words, since the numerous presence of carbonic anhydrase in the cardiovascular system can reduce the inhibitory effect of polmacoxib on COX-2, therefore it has a differentiated mechanism for mitigating possible adverse effects in the cardiovascular system.


The ability to bind to carbonic anhydrase does not affect the effectiveness of the drug, since KA is minimally present in the joints. Carbonic anhydrase does not interfere with the inhibition of COX-2 in the joints with anti-inflammatory analgesic action, and polmacoxib may be effective even at low doses.


Pharmacokinetics

Absorption of polmacoxib after oral administration occurs quickly, bioavailability is more than 95%.

Based on the data of clinical studies of polmacoxib, the following conclusions were made:

• polmacoxib is well absorbed in the body. There is statistically significant evidence of an increase in plasma concentration in proportion to the dose.

• there were no visible differences by race or gender.

• unlike other NSAIDs, polmacoxib can be used once a day.

• polmacoxib is well tolerated. Good tolerability allows the use of an oral shock dose to shorten the time to reach a steady plasma concentration. According to calculations, the required shock dose is 6-7 times more than the maintenance dose.


Indications for use

The drug Polmaxib® is indicated for the relief of signs and symptoms of osteoarthritis in adult patients. The drug is intended for symptomatic therapy, reducing pain and inflammation at the time of use, does not affect the progression of the disease.


Method of administration and dosage

Inside after eating.

Adults (over 18 years old): the recommended dose is 2 mg orally 1 time per day.


The duration of the course of therapy is up to 6 weeks. The decision on the need for a longer intake is made by the attending physician. The drug should not be taken for more than 24 weeks due to the lack of safety data for longer use.


Release form
Capsules 2 mg.

10 or 30 capsules in a jar.


Expiration date

3 years.

Vacation conditions
They are released by prescription.

The drug Polmaxib® is manufactured in the Republic of Korea.



  1. Patent No. RU 2681932

  2. Kim HT, Cha H2, Hwang KY3.Structural insight into the inhibition of carbonic anhydrase by the COX-2-selective inhibitor polmacoxib (CG100649). Biochem Biophys Res Commun. 2016 Sep 9;478(1):1-6.

  3. Overview of Acelex® (Polmacoxib), a Novel NSAID for Osteoarthritis. http://slideplayer.com/slide/10601860/

Instructions for the medical use of the drug Polmaxib® RU LP-007663 from 07.12.2021.

ПРЕДУПРЕЖДЕНИЕ

Информация в разделе предназначена исключительно для медицинских работников.


Подтвердите, пожалуйста, являетесь ли Вы медицинским работником.


Если Вы не являетесь медицинским работником, пожалуйста, покиньте данный раздел сайта.

Да, я медицинский работник
Нет, я не медицинский работник
Закрыть
Ask a Question
Your name*
Проверка ошибки
Email*
Проверка ошибки
Phone number*
Проверка ошибки
Product Name*
Проверка ошибки
Question text
Your question has been successfully sent, we will contact you as soon as possible